Research programme: inflammation endothelial cell therapy - Shire

Drug Profile

Research programme: inflammation endothelial cell therapy - Shire

Alternative Names: PVS-40200

Latest Information Update: 18 Jun 2014

Price : $50

At a glance

  • Originator Pervasis Therapeutics
  • Developer Shire
  • Class Cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Inflammation

Most Recent Events

  • 18 Jun 2014 Discontinued for Inflammation in USA (unspecified route)
  • 19 Apr 2012 Shire acquires all the assets of Pervasis Therapeutics
  • 01 Dec 2011 No development reported for Inflammation in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top